Does Livagen do anything Vesugen doesn't

Livagen and Vesugen come from the same Khavinson bioregulator family, get sold by the same handful of gray-market suppliers, and get asked about together constantly, so the comparison of livagen vs vesugen is a fair one to run straight. Short answer: Vesugen has real published data behind it, including a small human cohort, and Livagen has none. That gap mainly affects which one deserves your money.

I get this question from people who've already bought one or both and are trying to figure out if they wasted their money. I've spent a lot of time in the Khavinson literature because it's a strange corner of the peptide world: dense with decades-old Russian publications, thin on anything a Western reviewer would call rigorous, and yet still the source of two peptides people keep asking me about by name.

What each one actually is

Livagen is a tetrapeptide (Lys-Glu-Asp-Ala) aimed at the liver. Vesugen is a tripeptide (Lys-Glu-Asp) aimed at vascular endothelium, the lining of blood vessels. Both are proposed to work the way the rest of the Khavinson family works: crossing into the cell nucleus and nudging gene expression in a tissue-specific direction, in this case hepatocyte gene reactivation for Livagen and angiogenesis or endothelial repair for Vesugen. Neither claim has been confirmed with the kind of mechanistic study that would satisfy a skeptic, and I'm not going to pretend otherwise.

The evidence gap is the whole story

This is where the two compounds actually separate. Livagen's own encyclopedia entry lists zero studies conducted on the compound itself. The single citation tied to it is a 2004 in-vitro paper on chromatin decondensation in hepatocytes, and that paper only covers the Khavinson family's general mechanism claim, with no compound-specific Livagen trial anywhere in the record.

Vesugen isn't in a different evidence tier than the rest of this family, but it does have two real anchors. A 2021 paper ran daily injections in a severe transgenic mouse model of Alzheimer's disease and reported restored hippocampal spine density after two months, with a correction notice issued later over a figure mix-up that the authors say doesn't change the conclusions. That's animal data, and I label it that way every time it comes up. But there's also a small unblinded human cohort, 32 patients aged 41 to 83 with chronic health problems and organic brain syndrome in remission, where Vesugen was reported to slow biological aging markers more visibly than a companion peptide in the same study, though the trial was unblinded, small, and conducted at a single site in Russia. Still, it's a human study, and Livagen has nothing comparable at any tier.

So if you're asking which one has more behind it, Vesugen wins clearly. If you're asking which one is right for your goal, that's a separate question. Vesugen's data doesn't say anything about liver function, and Livagen's lack of published data simply means nobody has studied it yet.

Cost and side-effect load, practically the same

Neither compound carries documented serious adverse events. The family-wide profile reported in the older Russian literature is mild: occasional injection-site irritation, transient mild headache in the first few days of a cycle. Pricing between the two runs close, generally in the same range as other short synthetic peptides from the same suppliers, so cost isn't the deciding factor here.

Where I do want you paying attention is the supply chain, not the molecule. Khavinson-family peptides are the most heavily counterfeited category I see in this space, and a compound with almost no independent published literature, which describes both of these, is an easy target for mislabeling because there's so little to check a vendor's claims against. A certificate of analysis you can actually read matters more here than for almost anything else in the catalog. Heads up: OHM has an affiliate relationship with some of the vendors we link to for testing and sourcing resources, so we may earn a commission if you buy through one of those links, and it doesn't change which peptide the evidence actually supports.

Dosing, and who each one actually suits

Now the part my lawyer makes me say, and he's right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Neither peptide has a validated human dose-finding trial. What exists for both is the same Khavinson-school convention: a short course of 10 to 20 days, repeated 2 to 3 times a year, with community subcutaneous dosing converging around 100 to 200 mcg per day. The 2021 Vesugen mouse study used 400 mcg per kg by injection daily, which is a much higher dose than the human community protocol and isn't directly convertible to it. This is the dosing people actually run for both compounds, without any validated dose-finding trial behind it.

Fit matters more than the research gap. If your interest is genuinely liver-focused, Livagen sits in that lane alongside pancragen and ovagen, and Vesugen's vascular and cognitive data doesn't transfer over no matter how much more of it exists. If your interest is vascular support, cognitive aging, or you were drawn in by the Alzheimer's-model result, Vesugen is the one with something to point to, thin as it is. I try to stay evidence-based with peptides, and in this pair, one side of this comparison is mostly a mechanism story while the other has, at minimum, a human cohort worth reading.

If you're weighing this family against better-studied options for energy or metabolic goals instead, 5-Amino-1MQ sits on much firmer ground, and it's worth knowing that before you commit a cycle to either Khavinson peptide.